Madhya Pradesh Online Journal

The EGFR Inhibitors-Induced Skin Disorders Market Size is anticipated to increase during the study period, 2019-2032 | Key Companies – AstraZeneca, Pfizer, and Several Others

 Breaking News
  • No posts were found

The EGFR Inhibitors-Induced Skin Disorders Market Size is anticipated to increase during the study period, 2019-2032 | Key Companies – AstraZeneca, Pfizer, and Several Others

September 15
09:28 2022
The EGFR Inhibitors-Induced Skin Disorders Market Size is anticipated to increase during the study period, 2019-2032 | Key Companies - AstraZeneca, Pfizer, and Several Others

“The increase in EGFR Inhibitors-Induced Skin Disorders market size is a direct consequence of an increase in R&D activity, increasing prevalent population, expected commercial success of upcoming therapies in the 7MM”

 

EGFR Inhibitors-Induced Skin Disorders Market is expected to gain market growth in the forecast period of 2022 to 2032. The growing cases of tumors will directly impact the growth of the EGFR Inhibitors-Induced Skin Disorders market.

 

The increase in EGFR Inhibitors-Induced Skin Disorders market size is a direct consequence of the increasing disease prevalence and potential launch of novel medical therapies for EGFR Inhibitors-Induced Skin Disorders in the 7MM.

 

Key highlights from the EGFR Inhibitors-Induced Skin Disorders Market Report

  • According to DelveInsight, the EGFR Inhibitors-Induced Skin Disorders market in 7MM is expected to witness a major change in the study period 2019-2032
  • According to DelveInsight, in 2021, among five cancer types most cases of EGFR Inhibitors-Induced Skin Disorders were from NSCLC followed by colorectal cancer, in the US.
  • As per DelveInsight analysis, the United States had a high number of cases of EGFR inhibitors use in cancers making up to around 60,000 cases in 2021.
  • EGFR Inhibitors-Induced Skin Disorders Market Companies included AstraZeneca, Pfizer, Novartis Pharmaceuticals, Janssen Research & Development, Yuhan Corporation/ Janssen Research & Development, Takeda, and several others
  • EGFR Inhibitors-Induced Skin Disorders Market Therapies included LUT014, HT-001/WEG232 (Aprepitant), and several others

 

Interested to know more about the ongoing developments in the EGFR Inhibitors-Induced Skin Disorders Market Report? Visit here- EGFR Inhibitors-Induced Skin Disorders Market Outlook

 

EGFR Inhibitors-Induced Skin Disorders Overview

The epidermal growth factor receptor (EGFR) is a transmembrane protein that regulates multiple cellular processes. The EGFR inhibitor is a class of targeted antitumor agents designed to bind to the EGFR, thereby preventing its activity. The US FDA, the EMA, and the PMDA have approved several drugs in this class, and associated side effects have also been noticed.

The most common side effects of EGFR-targeted therapies are dermatologic toxicities. EGFR inhibitor-mediated dermatologic side effects include an acneiform skin rash, hyperpigmentation, xerotic skin, pruritus, skin fissures, nail changes, and disorders of mucous membranes, eyes, and hair.

 

EGFR Inhibitors-Induced Skin Disorders Epidemiology Insights

The cutaneous side effects seem to be largely independent of the type of EGFR inhibitors used, and combined treatment with the monoclonal antibody cetuximab and the TKI erlotinib lead to side effects similar to those induced by treatment with the individual drugs.

 

EGFR Inhibitors-Induced Skin Disorders Epidemiology Segmentation in the 7MM

  • Total Number of Cases of EGFR Inhibitors-Induced Skin Disorders by Cancer Type
  • Total Cases of EGFR Inhibitors-Induced Skin Disorders

 

Discover more relevant information on the EGFR Inhibitors-Induced Skin Disorders Market Research Report here- EGFR Inhibitors-Induced Skin Disorders Market Size

 

EGFR Inhibitors-Induced Skin Disorders Treatment Market

EGFR inhibitor-related skin reactions treatment is not standardized, and accounts in the literature are based on local practice and mainly derived from personal, albeit extensive, experience. Currently, there is no approved therapy specific for anti-EGFR-induced skin diseases in the US, EU, and Japan. The off-label therapeutic options used for anti-EGFR-induced skin diseases are sunscreen, emollients and soap substitutes, antibiotics, antihistamines, topical steroids, and cosmetics.

 

EGFR Inhibitors-Induced Skin Disorders Therapeutics Market

The market has a critical unmet need for approved therapies specific to EGFR inhibitor-induced skin disorders. The treatment is mainly based on off-label therapies with limited safety and efficacy data. Corticosteroid use is also often limited due to their toxicity on long-term use.

 

EGFR Inhibitors-Induced Skin Disorders Market Landscape

The treatment of EGFR inhibitor-related skin reactions is not standardized, and accounts in the literature are based on local practice and mainly derived from personal, albeit extensive, experience.

 

EGFR Inhibitors-Induced Skin Disorders Emerging Therapy Assessment

EGFR Inhibitors-Induced Skin Disorders pipeline possesses potential drugs in mid stage developments to be launched in the near future. The major key players include Lutris Pharma Ltd., Hoth Therapeutics, among others hold the potential to create a significant positive shift in EGFR Inhibitors-Induced Skin Disorders market.

 

Read more about the EGFR Inhibitors-Induced Skin Disorders Key Players and Therapies in the reportEGFR Inhibitors-Induced Skin Disorders Market Companies

 

Scope of the EGFR Inhibitors-Induced Skin Disorders Market Report

  • Coverage- 7MM
  • Study Period- 2019-2032
  • Forecast Period- 2022-2032
  • EGFR Inhibitors-Induced Skin Disorders Market Companies included AstraZeneca, Pfizer, Novartis Pharmaceuticals, Janssen Research & Development, Yuhan Corporation/ Janssen Research & Development, Takeda, and several others
  • EGFR Inhibitors-Induced Skin Disorders Market Therapies included LUT014, HT-001/WEG232 (Aprepitant), and several others
  • Market Drivers and Barriers
  • KOL Views
  • Market Access and Reimbursement

 

Table of Content

1. Key Insights

2. EGFR Inhibitors-Induced Skin Disorders Executive Summary

3. Competitive Intelligence Analysis for EGFR Inhibitors-Induced Skin Disorders

4. EGFR Inhibitors-Induced Skin Disorders: Market Overview at a Glance

5. EGFR Inhibitors-Induced Skin Disorders: Disease Background and Overview

6. Patient Journey

7. EGFR Inhibitors-Induced Skin Disorders Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. EGFR Inhibitors-Induced Skin Disorders Unmet Needs

10. Key Endpoints of EGFR Inhibitors-Induced Skin Disorders Treatment

11. EGFR Inhibitors-Induced Skin Disorders Marketed Products

12. EGFR Inhibitors-Induced Skin Disorders Emerging Therapies

13. EGFR Inhibitors-Induced Skin Disorders: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: EGFR Inhibitors-Induced Skin Disorders Market Outlook

16. Access and Reimbursement Overview of EGFR Inhibitors-Induced Skin Disorders

17. KOL Views

18. EGFR Inhibitors-Induced Skin Disorders Market Drivers

19. EGFR Inhibitors-Induced Skin Disorders Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

Got Queries? Read more information about the EGFR Inhibitors-Induced Skin Disorders Market Report- https://www.delveinsight.com/sample-request/egfr-inhibitors-induced-skin-disorders-market

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/